

# Future trends of drug resistance and prospects of antiviral therapy

---

**Doug Richman**

**International Drug Resistance Workshop**

**Johannesburg**

**24 October 2018**



- **The principles of HIV drug resistance are well established (Darwinian evolution).**
- **The mistakes and lessons learned in the developed world are being recapitulated in low and middle income countries.**

# **HIV drug resistance is generated by one of two major mechanisms**




---

- **Acquired drug resistance following non-suppressive treatment (secondary resistance)**
- **Transmitted drug resistance (TDR) (primary resistance)**





**(PDR combines both TDR and resistance acquired from previous treatment, disclosed or not, after infection)**

- **Both mechanisms are too prevalent.**
- **Prevention strategies for these two mechanisms are completely different.**

# Diminishing drug resistance with superior regimens



# If resistance appears, it is often less fit resulting in lower viral loads



# How did this reduction in resistance with more expanded treatment happen?

---

- **Better drugs**
  - More potent and better half-lives (TDF/FTC, better PIs, integrase inhibitors)
  - More tolerable and less toxic
  - Introduction of several new compounds at the same time
  - Multiple fixed dose combinations
- **Better monitoring of failure and then use of drug resistance testing and better drugs for treatment failure**


**All this happened before the availability of second generation integrase inhibitors.**

**Now, how do we approach the availability of TID or TFD**

# Virological suppression of individuals on ART in South Africa



- Data from 69,454 patients on 1<sup>st</sup> line ART
- 57 rural and urban clinics
- Monitoring according to SA guidelines




time	26.0	52.0	78.0	104.0	130.0	156.0	182.0	208.0	234.0	260.0	286.0	312.0
n_at_risk	17340.0	28360.0	30713.0	30190.0	25852.0	21966.0	17875.0	14256.0	11097.0	8975.0	6881.0	5502.0
VL_below_50_OT	70.0	74.2	75.8	76.4	77.1	77.5	78.1	78.5	79.1	78.7	79.0	79.9
VL_51_999_OT	18.9	14.5	12.6	12.2	11.9	11.8	11.3	11.3	10.9	10.6	10.5	10.2
VL_above_1000_OT	11.2	11.3	11.6	11.5	11.0	10.7	10.5	10.3	10.1	10.7	10.5	10.0

# Low-level viremia increases risk of viral rebound



- Data from same dataset
- Association corrected for demographics, baseline CD4
- Risk also increased for confirmed failure and switch



	Adjusted HR (95% CI)	p value
Virological suppression <50 copies per mL	1 (ref)	..
LLV 51-999 copies per mL	2.6 (2.5-2.8)	<0.0001
LLV 51-199 copies per mL	1.9 (1.8-2.1)	<0.0001
LLV 200-399 copies per mL	3.2 (2.9-3.5)	<0.0001
LLV 400-999 copies per mL	4.7 (4.2-5.2)	<0.0001

# In case of failure: Switch of ART is seriously delayed



- Observed clinical practice is delayed in comparison to guideline-recommended practice
- VL is measured repeatedly after rebound
- Switch is often postponed or not performed at all

Clinical follow-up of viral rebound: Observed versus recommended practice



**Table 22: Estimates of HIV drug resistance among people failing ART, by study/cohort and region in the acquired HIV drug resistance literature review in adults**


Country	Study author	% with resistance	CI (%)
<b>Africa</b>			
Cameroon	Zoufaly et al.	71%	54.1–84.6
Guinea	Diouara et al.	68%	47.6–84.1
Kenya	Hassan et al.	53%	38.8–66.3
Kenya	Kantor et al.	91%	78.7–97.5
Kenya	Koigi et al.	41%	26.3–56.7
Liberia	Loubet et al.	71%	55.9–83
Mali	Diouara et al.	93%	68–99.8
Mali	Fofana et al.	92%	83.5–96.5
Mauritania	Fall-Malick et al.	73%	59.7–83.6
Mozambique	Bila et al.	47%	30.4–64.5
Mozambique	Ruperez et al.	89%	77.7–95.2
Senegal	Diouara et al.	70%	49.8–86.2
Senegal	Diouara <sup>1</sup> et al.	79%	65.3–88.9
Togo	Konou et al.	99%	96.6–99.9

# The levels of acquired drug resistance requires addressing the causes



- **The patient**
  - adherence
- **The prescribing care provider**
  - selecting an optimal regimen
  - counseling the patient
- **The drugs**
  - Potency
  - tolerability
  - Pharmacokinetics
- **The healthcare delivery system**
  - Provide viral load monitoring with prompt turnaround and threshold <100 copies/mL
  - Provide assays for drug resistance (or drug levels).
  - Avoid stockouts

# Rapid Suppression of HIV-1 RNA to < 50 copies/mL through Week 48 (Missing = Excluded Approach)



**B/F/TAF vs. DTG/ABC/3TC or vs. DTG + F/TAF:  
displayed rapid viral suppression and non-inferior efficacy at Week 48**

AE=adverse event; DC=discontinuation; Other reasons= lost to follow-up, withdrew consent, investigator discretion, noncompliance, etc.)

# Molepolole District

- 709 Chart reviews completed 78.9% (560) with viral load results at 12 months – All Cohorts:

4 (<1%)	VL >400 copies/mL
6 (1%)	LTFU
3 (<1%)	Deaths (2 TB related, 1 unknown)
2 (<1%)	Toxicity Grade 3

**97.6%** (548/560)

*Viral Load <400 copies/mL at 12 months*

# Switches to DTG Outcomes

Reason for Switch	#	% VL <400 6 months	%VL 400 12 months
Guidelines Simplification	33	10/11 (90.9%)	20/22 (90.9%)
Toxicities	173	85/87 (97.7%)	85/86 (98.8%)
Tx Failure	135	27/37 (72.9%)	94/98 (95.9%)
<b>Totals</b>	<b>341</b>	<b>122/135 (90.3%)</b>	<b>199/206 (96.6%)</b>

# Measures are still needed to preserve the integrase class over time - 1

- **Low level viremia ≠ treatment success**
  - High threshold may be even more dangerous with DTG, since viruses resistant to DTG are often not very fit and viral load may remain low
- **Delayed response to viral rebound puts individuals and society at risk**
- **Use tools** (like viral load monitoring and objective adherence assessment) **to generate insight in virological failure**

# Measures are still needed to preserve the integrase class over time - 2

- Avoid adding 1 new drug to a failing regimen
  - What is the risk of a switch from a failing regimen with TLE to TLD?
  - Surveillance in those who start DTG with unsuppressed viral load should be promptly initiated if resistance testing is not applied at switch

# Acknowledgements

- Ava Alves
- Itrema team
  - Lucas Hermans
  - Annemarie Wensing
  - Monique Nijhuis